First Affiliated Hospital of ZhengzhouUniversity

Zhengzhou, Henan 450052

0 studies enrolling now · 2 studies all time

What they study most

Breast Cancer, HER2 Exon 20 Mutation, Non-squamous NSCLC, TNBC - Triple-Negative Breast Cancer

Studies at this site

• Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy — Completed
• Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC) — Completed